July 31, 2025

New Member: Welcome in our cluster to Fab’ulous SAS

New Member: Welcome in our cluster to Fab’ulous SAS
Go back

Fabulous accelerates antibody discovery with a fully computational, AI-powered approach that delivers preclinical ready human antibodies in just 3–5 days. Starting from your scientific problem, it designs candidates using curated human sequence data and in silico maturation to mimic natural immune evolution. This process enhances affinity, thermostability, and expression while reducing off-target binding. Each sequence is custom-built to meet IP, manufacturability, and payload needs, enabling faster R&D cycles and dramatically lowering costs across a wide range of therapeutic and diagnostic targets.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
New Member: Welcome in our cluster to Fab’ulous SAS

New Member: Welcome in our cluster to Fab’ulous SAS

Fabulous accelerates antibody discovery with a fully computational, AI-powered approach that delivers preclinical ready human antibodies in just 3–5 days. Starting from your scientific problem, it designs candidates using curated human sequence data and in silico maturation to mimic natural immune evolution. This process enhances affinity, thermostability, and expression while reducing off-target binding. Each sequence […]

read more
AGC Biologics’ Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva’s Tetravalent Shigella Vaccine Candidate

AGC Biologics’ Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva’s Tetravalent Shigella Vaccine Candidate

SEATTLE AND HEIDELBERG – July 29, 2025 – AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) to supply drug substance for an investigational four-valent Shigella bioconjugate vaccine at the CDMO’s Heidelberg facility.   Valneva exclusively licensed the vaccine candidate from LimmaTech Biologics AG, which […]

read more
From bench to code: collaboration unlocks insights into Alzheimer’s disease

From bench to code: collaboration unlocks insights into Alzheimer’s disease

How a chance encounter at a scientific conference resulted in a fruitful cross-Atlantic research collaboration In 2023, EMBL-EBI Postdoctoral Fellow Iguaracy Pinheiro de Sousa presented his bioinformatics work on how cells communicate within the heart, as part of the Network Biology meeting in Cold Spring Harbour, New York. “I met Yifei Cai during the opening […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp